市場調查報告書
商品編碼
1370463
生命科學市場中的人工智慧:2023-2028 年全球產業趨勢、佔有率、規模、成長、機會和預測Artificial Intelligence In Life Sciences Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球生命科學人工智慧市場規模達到19億美元。展望未來,IMARC Group預計到2028年市場規模將達到82億美元,2023-2028年年複合成長率(CAGR)為25.7%。
人工智慧 (AI) 是一種高度數據驅動的技術,用於生命科學中收集、分析和管理患者資料。它通常用於醫學診斷、臨床試驗、藥物發現、生物技術、患者監測、精準醫療和個人化醫療。它也用於生產個人化治療、配製藥物、診斷疾病以及引入療法和機器人手術。生命科學中的人工智慧有助於重塑商業模式,增強認知分子研究和工作流程,並簡化生物製藥製造。它還可以節省寶貴的時間、提高效率、降低整體成本、增強客戶體驗並消除人為錯誤。
目前,癌症等複雜疾病盛行率的上升是推動市場成長的關鍵因素之一。生命科學領域的人工智慧被廣泛應用於為患者設計具有特定分子標靶的有效藥物組合。此外,全球臨床試驗數量的不斷增加導致公共領域可用的大量資料激增。這反過來又為市場成長創造了有利可圖的機會。除此之外,引入可靠且先進的雲端運算基礎設施可以輕鬆管理、共享和儲存資料,並幫助根據要求改善組織營運,這為市場提供了推動力。此外,分析和解釋大量結構化和非結構化臨床資料的需求不斷成長,這是另一個成長誘導因素。除此之外,廣泛的研發(R&D)活動、機器人手術利用率的提高以及政府為推進醫療基礎設施而實施的各種舉措預計將推動市場在預測期內實現成長。
The global artificial intelligence in life sciences market size reached US$ 1.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.2 Billion by 2028, exhibiting a growth rate (CAGR) of 25.7% during 2023-2028..
Artificial intelligence (AI) is a highly data-driven technology that is used in life sciences to collect, analyze, and manage data of patients. It is commonly employed for medical diagnosis, clinical trials, drug discovery, biotechnology, patient monitoring, precision, and personalized medicine. It is also utilized for producing personalized treatments, formulating drugs, diagnosing diseases, and introducing therapies and robotic surgeries. AI in life sciences helps reshape business models, enhance cognitive molecule research and workflow, and streamline biopharmaceutical manufacturing. It also saves valuable time, improves efficiency, reduces overall costs, enhances customer experience, and eliminates human error.
At present, the rising prevalence of complex diseases, such as cancer, represents one of the key factors impelling the market growth. AI in life sciences is widely used to design effective drug combinations with specific molecular targets for patients. Additionally, the growing number of clinical trials across the globe is resulting in the surging production of colossal amounts of data available in the public domain. This, in turn, is creating lucrative opportunities for the market growth. Apart from this, the introduction of reliable and advanced cloud computing infrastructure that can easily manage, share, and store data and help improve organizational operations as per the requirements are providing a boost to the market. Moreover, the growing need to analyze and interpret large volumes of structured and unstructured clinical data is acting as another growth-inducing factor. Apart from this, extensive research and development (R&D) activities, rising utilization of robotics surgeries, and the implementation of various government initiatives to advance the medical infrastructure are anticipated to drive the market toward growth in the forecasted period.
IMARC Group provides an analysis of the key trends in each sub-segment of the global artificial intelligence in life sciences market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on offering, deployment and application.
Software
Hardware
Services
On-premises
Cloud-based
Drug Discovery
Medical Diagnosis
Biotechnology
Clinical Trails
Precision and Personalized Medicine
Patient Monitoring
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AiCure LLC, Apixio Inc. (Centene Corporation), Atomwise Inc, Enlitic Inc., International Business Machines Corporation, Insilico Medicine Inc., Nuance Communications Inc., NuMedii Inc., Sensely Inc. and Sophia Genetics SA.
Table 7 Global: Artificial Intelligence In Life Sciences Market: Key Players